BioCryst Announces Approval of Japanese NHI Price Listing of ORLADEYO™ (berotralstat) for Prophylactic Treatment of Hereditary AngioedemaGlobeNewsWire • 04/14/21
FDA Decisions For Pfizer, Eli Lilly And Bluebird Bio, Bristol-Meyers Squibb, Plus New Data And EarningsBenzinga • 03/20/21
BioCryst Appoints Helen Thackray, M.D., as Chief Research and Development OfficerGlobeNewsWire • 03/19/21
BioCryst, Editas, Groupon, Sunrun, Twitter and More of Monday Afternoon's Analyst Calls24/7 Wall Street • 03/01/21
BioCryst Receives Positive CHMP Opinion for ORLADEYO™ (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary AngioedemaGlobeNewsWire • 02/25/21
BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/25/21
BioCryst to Report Fourth Quarter and Full Year 2020 Financial Results on February 25GlobeNewsWire • 02/11/21
BioCryst to Present Data at 2021 American Academy of Allergy, Asthma & Immunology Annual MeetingGlobeNewsWire • 02/09/21
BioCryst Announces FDA Approval of Supplemental New Drug Application for RAPIVAB® Expanding Patient Population to Include Children Six Months and OlderGlobeNewsWire • 02/03/21
BioCryst surges 30% to a 5-year high as Redditors declare 'BioWar' against short-sellersBusiness Insider • 02/01/21